CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
2-HOBA +1 moredrug
Likely dose
2-HOBA 750mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05274243
NCT05274243Phase 2Completed
CompareCT.gov

2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis

Vanderbilt University Medical Center·interventional·Posted Mar 10, 2022·Updated Apr 8, 2026

In Brief

A Phase 2 clinical trial evaluating 2-HOBA and Placebo for Rheumatoid Arthritis. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is a phase 2 study to determine 2-HOBA's tolerability, safety, and effect on isoLG-adducts in patients with rheumatoid arthritis (RA) patients. Up to 32 subjects will be randomized to 750mg 2-HOBA or matching placebo three times a day for 4 weeks. As primary outcome measures investigators will compare tolerability and adverse events and changes in isoLG adducts in active and placebo arms. Among prespecified exploratory outcomes investigators will compare changes in markers of inflammation, DAS28 score, and 24-hour blood pressure in active and placebo arms. This pilot study will inform the feasibility and design of future studies to examine the efficacy of 2-HOBA in RA patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 10, 2022
Enrollment StartAug 9, 2022
Primary CompletionMay 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.3 years ago

Interventions

2-HOBAdrug

2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks

Placeboother

Placebo (provided as three capsules) three times a day for 4 weeks